Clinical trial
A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer
NCT07545811 is registered in ClinicalTrials.gov with Janux Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer
- Lead sponsor
- Janux Therapeutics
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 15, 2026
- Completion date
- March 31, 2029
- Enrollment
- 43 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, prostate cancer